On Wednesday, Guggenheim reaffirmed its Buy rating on Celldex (NASDAQ:CLDX) Therapeutics (NASDAQ:CLDX), maintaining the established price target. The firm addressed investor concerns following Celldex's announcement of 52-week data from its Phase II study of barzolvolimab for chronic spontaneous urticaria (CSU).
The study results revealed increased instances of neutropenia, now affecting 17% of participants, up from 9% at the 12-week mark. Other noted issues included hypopigmentation and two cases of macrocytic anemia.
Celldex provided additional information on the neutrophil counts, indicating stability after an initial decline, with no further long-term decrease. The company emphasized that no new Grade 3 adverse events have been reported, except for one case of neutropenia previously disclosed. According to Celldex, adverse events related to the drug's target, cKIT, are anticipated to be reversible.
Guggenheim's commentary also referenced feedback from Key Opinion Leaders (KOLs) confirming that the medical community is generally comfortable with barzolvolimab's profile as a second-line treatment for CSU. The firm suggests that the negative stock reaction to the data release, which saw Celldex shares drop 17% compared to a 1% decline in the XBI biotech index, is an overreaction.
The analyst from Guggenheim concluded that the long-term treatment with barzolvolimab does not lead to a further decline in neutrophil counts, supporting the drug's safety profile. The firm remains positive on the stock, recommending investors to buy on the current weakness. This endorsement comes despite the market's initial negative response to the clinical study's safety and tolerability findings.
In other recent news, Celldex Therapeutics has made significant strides in its ongoing research and development efforts. The company reported positive results from its Phase 2 studies on barzolvolimab, a potential treatment for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The studies revealed sustained efficacy and a well-tolerated safety profile, with 71% of CSU patients achieving a complete response after a 52-week treatment period.
Moreover, Celldex has initiated global Phase 3 trials for barzolvolimab in adults with CSU who have not responded adequately to H1 antihistamine treatments. The company has also completed patient enrollment for its Phase 2 trial of barzolvolimab for CIndU, with data expected later this year.
In the realm of financial analysis, Stifel reiterated its Buy rating for Celldex, maintaining a steady price target of $58.00. The firm's evaluation followed the presentation of full 52-week Phase 2 study results for CSU. Similarly, Wolfe Research assigned an Outperform rating to the company.
InvestingPro Insights
In light of Guggenheim's reaffirmation of a Buy rating on Celldex Therapeutics, a look at the company's financial health and stock performance offers additional context for investors. According to real-time data from InvestingPro, Celldex holds a market capitalization of $2.36 billion. Despite concerns over safety findings in its clinical study, the company's stock has demonstrated resilience with a notable 58.51% return over the past year. This aligns with the InvestingPro Tip highlighting the company's strong return over the last year. Additionally, Celldex's recent revenue growth is impressive, with a 155.16% increase over the last twelve months as of Q2 2024, which may be indicative of its potential for future growth.
However, it's worth noting that analysts do not anticipate Celldex will be profitable this year, and the company has been grappling with weak gross profit margins, as reflected in a gross profit margin of -1356.56% over the same period. These financial metrics underscore the challenges Celldex faces, even as it shows potential in revenue growth and stock performance. For investors seeking a deeper dive into the company's prospects, InvestingPro offers additional tips, including insights on the company's cash position relative to its debt and its liquidity status in meeting short-term obligations. To explore these further insights, investors can visit InvestingPro for a total of 11 additional tips on Celldex Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.